Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 12, Issue 7, pp. 1190-1201
PubMed
Published By
Print ISSN
Online ISSN
History
- Received December 4, 2012
- Revision received May 10, 2013
- Accepted May 10, 2013
- Published first May 21, 2013.
Article Versions
- Previous version (May 21, 2013 - 15:12).
- Previous version (June 5, 2013 - 13:53).
- Previous version (June 27, 2013 - 14:10).
- You are viewing the most recent version of this article.
Copyright & Usage
©2013 American Association for Cancer Research.
Author Information
- Katherine T. Ostapoff1,2,
- Niranjan Awasthi1,2,
- Bercin Kutluk Cenik2,
- Stefan Hinz1,2,4,
- Keith Dredge5,
- Roderich E. Schwarz1,2, and
- Rolf A. Brekken1,2,3
- Authors' Affiliations: 1Division of Surgical Oncology, Department of Surgery, 2Hamon Center for Therapeutic Oncology Research, 3Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, Texas; 4University of Lübeck, Lübeck, Germany; and 5Progen Pharmaceuticals Ltd., Brisbane, Queensland, Australia
- Corresponding Author:
Rolf A. Brekken, Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, 6000 Harry Hines Blvd, Dallas, TX 75390. Phone: 214-648-5151; Fax: 214-648-4940; E-mail: Rolf.Brekken{at}utsouthwestern.edu
July 2013
Volume 12, Issue 7
Volume 12, Issue 7
PG545, an Angiogenesis and Heparanase Inhibitor, Reduces Primary Tumor Growth and Metastasis in Experimental Pancreatic Cancer
Jump to section
Advertisement